Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells.

ABSTRACT:

Introduction

High failure rates of new investigational drugs have impaired the development of breast cancer therapies. One challenge is that excellent activity in preclinical models, such as established cancer cell lines, does not always translate into improved clinical outcomes for patients. New preclinical models, which better replicate clinically-relevant attributes of cancer, such as chemoresistance, metastasis and cellular heterogeneity, may identify novel anti-cancer mechanisms and increase the success of drug development.

Methods

Metastatic breast cancer cells were obtained from pleural effusions of consented patients whose disease had progressed. Normal primary human breast cells were collected from a reduction mammoplasty and immortalized with human telomerase. The

SUBMITTER: Gligorich KM 

PROVIDER: S-EPMC4028696 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature